-
UPDATE: Piper Jaffray Maintains Neutral, Lowers PT to $3 on Metabolix
Friday, January 13, 2012 - 9:17am | 122Piper Jaffray reiterates its Neutral rating on Metabolix (NASDAQ: MBLX) and lowers its price target ot $3 from $5 to reflect uncertainty in commercialization following ADM's dissolution of Telles. Piper Jaffray notes, "The announcement yesterday after market close that ADM terminated their vital...
-
Benzinga's Top Downgrades
Friday, January 13, 2012 - 8:44am | 148Analysts at Robert W. Baird downgraded Xueda Education Group (NYSE: XUE) from “outperform” to “neutral.” XUE's shares closed at $3.65 yesterday. Xueda Education's trailing-twelve-month profit margin is 7.37%. Morgan Stanley downgraded Shutterfly Inc (NASDAQ: SFLY) from “overweight” to “equal-...
-
A Peek Into The Market Before The Trading Starts
Friday, January 13, 2012 - 8:24am | 336Pre-open movers US stock futures are mixed this morning. Futures for the Dow Jones Industrial Average dropped 7 points to 12,406.00 and S&P 500 index futures fell 1.20 points to 1,290.50. Nasdaq 100 futures gained 0.50 points to 2,379.00. A Peek Into Global Markets European markets were...
-
UPDATE: Jefferies Downgrades Metabolix to Hold, Lowers PT to $4
Friday, January 13, 2012 - 7:58am | 110Jefferies lowers it rating on Metabolix (NASDAQ: MBLX) to Hold from Buy and lowers its price target to $4 from $9 on lack of forward visibility. Jefferies says, "The termination of Telles by ADM (ADM, $29.14, NC) illustrates one of the challenges faced by the capital-intensive renewables sector:...
-
US Stock Futures Mixed; J.P. Morgan Earnings In Focus
Friday, January 13, 2012 - 7:27am | 340US stock futures are mixed this morning, as investors are awaiting earnings from J.P. Morgan Chase & Co (NYSE: JPM). Futures for the Dow Jones Industrial Average dropped 10 points to 12,403.00 and S&P 500 index futures fell 1.40 points to 1,290.30. Nasdaq 100 futures gained 0.50 points to 2...
-
Jefferies Downgrades Metabolix to Hold
Friday, January 13, 2012 - 7:12am | 27Jefferies & Company has downgraded Metabolix (NASDAQ: MBLX) from Buy to Hold and has lowered the price target from $9 to $4.
-
Piper Jaffray Lowers PT on Metabolix to $3
Friday, January 13, 2012 - 7:05am | 26Piper Jaffray has lowered the price target on Metabolix (NASDAQ: MBLX) from $5 to $3 and maintains its Neutral rating.
-
Stocks To Watch For January 13
Friday, January 13, 2012 - 4:20am | 215Some of the stocks that may grab investor focus today are: JDA Software Group Inc (NASDAQ: JDAS) issued weak fourth-quarter revenue forecast. The company projects revenue of about $173 million for the fourth quarter, versus analysts' estimates of $181.6 million. JDAS shares tumbled 12.20% to $28....
-
UPDATE: ADM to End Commercial Alliance with Metabolix
Thursday, January 12, 2012 - 5:34pm | 102Archer Daniels Midland Company (NYSE: ADM) announced today that ADM Polymer Corporation, a wholly owned subsidiary of ADM, will end its commercial alliance with Metabolix, Inc. (NASDAQ: MBLX) on February 8, 2012. As a result of this decision, Telles LLC, the sales and marketing commercial alliance...
-
Metabolix Announces Termination of Telles Joint Venture
Thursday, January 12, 2012 - 5:06pm | 56Metabolix, Inc. (NASDAQ: MBLX), today announced that the Archer Daniels Midland Company has given notice of termination of the Telles, LLC joint venture for PHA bioplastics. The effective date of the termination will be February 8, 2012. Metabolix will hold a webcast conference call for investors...
-
Maxygen Announces $10 Million Stock Repurchase Program
Tuesday, January 10, 2012 - 9:00am | 73Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company, today announced that its Board of Directors has approved a new stock repurchase program under which the company may purchase up to $10.0 million of its common stock through December 31, 2012. Under its prior repurchase program, which expired at...
-
LX4211 Enhances Effects of DPP-4 Inhibition in Patients with Type 2 Diabetes
Monday, January 9, 2012 - 5:30pm | 274Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today top-line results from the first clinical study testing the combined effects of LX4211, a novel sodium glucose transporter 1 and 2 (SGLT1 and SGLT2) inhibitor, with the dipeptidyl peptidase 4 (DPP-4) inhibitor, sitagliptin (Januvia®), one...
-
Ligand Enters into Platform Captisol License and Supply Agreements with Lilly; Terms Not Disclosed
Wednesday, December 21, 2011 - 9:03am | 183Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it has entered into platform Captisol® license and supply agreements with Eli Lilly and Company (NYSE: LLY) in undisclosed therapeutic areas. During the collaboration, Lilly will be permitted to nominate an unlimited number of...
-
Luna Innovations Sets New Strategy for Future
Thursday, December 15, 2011 - 10:06am | 121Luna Innovations Incorporated (NASDAQ: LUNA) has announced a new corporate strategy to grow revenue that focuses on serving high-growth industries with new technology solutions to measure, monitor, protect and improve critical processes in the medical, defense and composites industries. The...
-
UPDATE: Jefferies Maintains Buy, Lowers PT to $9 on Metabolix
Tuesday, December 13, 2011 - 7:50am | 91Jefferies reiterates its Buy rating on Metabolix (NASDAQ: MBLX) and lowers its Price target to $9 from $13 as coming year's operations are dependent on CJ & Telles customer trade-offs. Jefferies says, “Metabolix is at a crossroads in 2012, with Telles facing a trade-off between how fast it...